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ABSTRACT
OBJECTIVE
To estimate the changes in life expectancy and years 





37 upper-middle and high income countries or regions 
with reliable and complete mortality data.
PARTICIPANTS
Annual all cause mortality data from the Human 
Mortality Database for 2005-20, harmonised and 
disaggregated by age and sex.
MAIN OUTCOME MEASURES
Reduction in life expectancy was estimated as the 
difference between observed and expected life 
expectancy in 2020 using the Lee-Carter model. 
Excess years of life lost were estimated as the 
difference between the observed and expected 
years of life lost in 2020 using the World Health 
Organization standard life table.
RESULTS
Reduction in life expectancy in men and women was 
observed in all the countries studied except New 
Zealand, Taiwan, and Norway, where there was a gain 
in life expectancy in 2020. No evidence was found of 
a change in life expectancy in Denmark, Iceland, and 
South Korea. The highest reduction in life expectancy 
was observed in Russia (men: −2.33, 95% confidence 
interval −2.50 to −2.17; women: −2.14, −2.25 to 
−2.03), the United States (men: −2.27, −2.39 to 
−2.15; women: −1.61, −1.70 to −1.51), Bulgaria 
(men: −1.96, −2.11 to −1.81; women: −1.37, −1.74 
to −1.01), Lithuania (men: −1.83, −2.07 to −1.59; 
women: −1.21, −1.36 to −1.05), Chile (men: −1.64, 
−1.97 to −1.32; women: −0.88, −1.28 to −0.50), and 
Spain (men: −1.35, −1.53 to −1.18; women: −1.13, 
−1.37 to −0.90). Years of life lost in 2020 were higher 
than expected in all countries except Taiwan, New 
Zealand, Norway, Iceland, Denmark, and South Korea. 
In the remaining 31 countries, more than 222 million 
years of life were lost in 2020, which is 28.1 million 
(95% confidence interval 26.8m to 29.5m) years of 
life lost more than expected (17.3 million (16.8m to 
17.8m) in men and 10.8 million (10.4m to 11.3m) 
in women). The highest excess years of life lost per 
100 000 population were observed in Bulgaria (men: 
7260, 95% confidence interval 6820 to 7710; women: 
3730, 2740 to 4730), Russia (men: 7020, 6550 
to 7480; women: 4760, 4530 to 4990), Lithuania 
(men: 5430, 4750 to 6070; women: 2640, 2310 to 
2980), the US (men: 4350, 4170 to 4530; women: 
2430, 2320 to 2550), Poland (men: 3830, 3540 to 
4120; women: 1830, 1630 to 2040), and Hungary 
(men: 2770, 2490 to 3040; women: 1920, 1590 to 
2240). The excess years of life lost were relatively low 
in people younger than 65 years, except in Russia, 
Bulgaria, Lithuania, and the US where the excess 
years of life lost was >2000 per 100 000.
CONCLUSION
More than 28 million excess years of life were lost 
in 2020 in 31 countries, with a higher rate in men 
than women. Excess years of life lost associated with 
the covid-19 pandemic in 2020 were more than five 
times higher than those associated with the seasonal 
influenza epidemic in 2015.
Introduction
Since the emergence of SARS-CoV-2, health policy 
measures employed to minimise the impact of 
the covid-19 pandemic have varied substantially 
across countries and jurisdictions.1-7 These policy 
measures have affected many social and economic 
determinants of health,8-11 including accessibility 
to healthcare services.12-15 The overall impact of 
the pandemic and its associated policy measures 
therefore have implications for mortality beyond 
deaths with covid-19—the accuracy and completeness 
of which has been questioned in many countries and 
jurisdictions.2 16
For numbered affiliations see 
end of the article
Correspondence to: N Islam  
nazrul.islam@ndph.ox.ac.uk 
(ORCID 0000-0003-3982-4325)
Additional material is published 
online only. To view please visit 
the journal online.
Cite this as: BMJ 2021;375:e066768 
http://dx.doi.org/10.1136/ 
bmj-2021-066768
Accepted: 6 October 2021
WHAT IS ALREADY KNOWN ON THIS TOPIC
Reported numbers of deaths with covid-19 are subject to changes within 
and across countries as well as some degrees of delays, inaccuracy, and 
incompleteness
Excess deaths (difference between observed and expected numbers of deaths 
from all causes) allows the assessment of the full impact of the pandemic, 
including the direct effect on deaths with covid-19, and the indirect effect of the 
pandemic on deaths from other diseases
Estimation of excess deaths does not, however, consider the age at death, and 
therefore does not quantify the impact of the pandemic on premature deaths as 
years of life lost (YLL)
WHAT THIS STUDY ADDS
In 2020, life expectancy was lower and YLL higher than expected in all countries 
except New Zealand, Taiwan, Iceland, South Korea, Denmark, and Norway—in the 
remaining 31 countries, >28 million excess years of life were lost
Highest reduction in life expectancy in 2020 was observed in Russia (men, 
−2.33 years; women, −2.14), the US (men, −2.27; women, −1.61), Bulgaria (men 
−1.96; women, −1.37), Lithuania (men, −1.83; women, −1.21), Chile (men, 
−1.64; women, −0.88), and Spain (men, −1.35; women, −1.13)
Excess YLL rates associated with the covid-19 pandemic in 2020 were more than 
five times higher than those associated with the seasonal influenza epidemic in 
2015
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Data on all cause mortality are considered more 
reliable indicators of the impact of the covid-19 
pandemic because they are less sensitive to 
coding errors, competing risks, and the potential 
for misclassification in designating the cause of 
deaths, and as such enable comparisons between 
countries.17-21 We have previously reported a large 
difference between reported deaths with covid-19 and 
estimated excess deaths associated with the covid-19 
pandemic in 2020.22 Previous studies have used 
historical baseline mortality data over the recent past 
to estimate the expected number of deaths in 2020 
and provide the basis for estimating excess deaths 
(observed minus expected deaths), which capture 
both the direct (deaths with covid-19) and the indirect 
(deaths from other causes) effects of the pandemic and 
associated policy measures.18-22 Although using excess 
deaths has been considered the ideal method for 
measuring the impact of the pandemic,15 this metric 
does not take into account age at death. When people 
die at an older age, they lose fewer years of remaining 
life.23 24 Analysis of life expectancy and years of life lost 
(YLL) provide a more nuanced estimation of premature 
mortality at population level. Life expectancy, a widely 
used metric of mortality, is an indication of how long 
on average people can expect to survive if the age 
specific mortality rates of that year remain constant for 
the remainder of their life.25 26 YLL takes into account 
the age distributions of mortality by giving greater 
weights to deaths that occur at younger ages.24 An 
important difference exists between life expectancy 
and YLL. Whereas life expectancy is a standardised 
measure based on a hypothetical life table cohort, YLL 
is calculated from the numbers of deaths observed in 
real populations. Therefore, life expectancy depends 
solely on mortality, and YLL (even after dividing by 
population size) depends on both the mortality and the 
age structure of the population.
Previous studies have reported the effects of the 
pandemic on reduction in life expectancy in the 
United States,27 28 England and Wales,29 and Spain,26 
largely based on partial data in 2020. Earlier studies 
have reported the YLL based on deaths with covid-19 
only.23 30-32 This method has several limitations 
because deaths with covid-19 were reported to have 
varying degrees of accuracy and incompleteness2 16 
23; covid-19 mortality data are often not disaggregated 
by age and sex, which are required for the calculation 
of YLL2; and the impact of the pandemic and its 
associated policy measures on deaths from other 
causes are not captured.15 22 A recent study by Aburto 
and colleagues examined changes in life expectancy 
between 2019 and 2020 in 29 developed countries 
and provided important information on differences 
between countries, including the best and the worst 
performers.33 However, this study was based on 
preliminary death statistics for reported countries 
and did not include data from Canada, Israel, Latvia, 
Luxembourg, New Zealand, Russia, South Korea, and 
Taiwan. The study did not report on the change in YLL 
either.
Most earlier studies compared life expectancy or 
YLL in 2020 with that in 2019 or an average of the 
most recent few years, which might lead to incorrect 
conclusions (see supplementary file).
In this study, we report the changes in life 
expectancy at birth and excess YLL from all causes in 
2020 by comparing the observed life expectancy and 
YLL in 2020 with those that would be expected based 
on historical trends in 2005-19 in 37 high income 
countries.
Methods
Study design and eligibility
This study is a time series analysis of annual data on 
all cause mortality obtained from 37 upper-middle 
and high income countries with reliable, valid, and 
complete mortality data between 2005 and 2020 
disaggregated by age and sex.
Source of data
We obtained data from the Human Mortality 
Database, in which mortality and population data 
from authoritative national agencies are collated 
and standardised. The database is maintained by 
the Department of Demography at the University of 
California, Berkeley, US and the Max Planck Institute 
for Demographic Research, Rostock, Germany.34  35 
Mortality data for 2020 were obtained from the 
Short-term Mortality Fluctuations data series (a new 
extension of the Human Mortality Database).36 For the 
purposes of this study, we required annual mortality 
data to be disaggregated by age groups (<1, 1-4, 
5-9, . . . 90-95, and ≥100) and sex.
Data for 2020 were available for 37 countries: 
Austria, Belgium, Bulgaria, Canada, Chile, Croatia, 
Czech Republic, Denmark, England and Wales, 
Estonia, Finland, France, Germany, Greece, Hungary, 
Iceland, Israel, Italy, Latvia, Lithuania, Luxembourg, 
the Netherlands, New Zealand, Northern Ireland, 
Norway, Poland, Portugal, Russia, Scotland, Slovakia, 
Slovenia, South Korea, Spain, Sweden, Switzerland, 
Taiwan, and the US. Details on the source and the 
methodology for collection and standardisation of 
data from each of these countries or regions have 
been published previously.36-38 In many countries, 
age groups originally available in Short-term Mortality 
Fluctuations data differed somewhat from the required 
granular age scale in this study. In six countries 
(Canada, Israel, Germany, New Zealand, South 
Korea, and the US) Short-term Mortality Fluctuations 
data included relatively coarse age groups (see 
supplementary file).
Statistical analysis
Calculation of life expectancy and YLL in 2020 and 
2015
Whenever possible, we used annual estimates from the 
Human Mortality Database based on official data (see 
supplementary file). Using the available data series 
in the Human Mortality Database starting from 2005, 
we employed the Lee-Carter model39 to extrapolate 
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annual death rates, which consequently serve as the 
input to estimate age specific population exposures 
and expected death counts under the assumption of 
zero migration. Expected age specific death rates were 
predicted separately for men and women. We obtained 
expected death counts and population exposures for 
both men and women by summing the data for each. 
We used the forecasted population exposures and 
observed death counts from the Short-term Mortality 
Fluctuations data series to calculate observed death 
rates for countries where annual estimates for 
2020 were not available from the Human Mortality 
Database.
Before calculating observed age specific death rates, 
we standardised the death counts from Short-term 
Mortality Fluctuations according to the International 
Organization for Standardization 8601-2004 
guidelines36 and adjusted for incomplete weekly death 
statistics in 2020. The age and sex specific adjustment 
coefficients for incompleteness were calculated using 
the average annual ratio of the Short-term Mortality 
Fluctuations data (ie, sum of weekly death counts) to 
annual death counts during the past five years.
In the absence of detailed mortality data by granular 
age groups, especially at young ages (eg, <1, 1-4 years) 
and old ages (eg, 85-89, 90-94 years) for 2020 in Short-
term Mortality Fluctuations, we split aggregated age 
groups using distribution of forecasted death counts 
from the Human Mortality Database (fig 1). Details of 
the methodology have been published previously.36 
We checked the accuracy of life expectancy estimates 
depending on granular or broad age intervals in the 
Short-term Mortality Fluctuations data and found 
only small deviations, even for broad age scales (see 
supplementary file for details of the methodology, 
including sensitivity analysis, and supplementary 
figures S1 and S2). For 2015 data, we used annual 
death counts and population exposures by five year 
age groups from the Human Mortality Database.
We derived life expectancy from abridged life tables, 
which were constructed using standard life table 
methodology.40 41 The supplementary file provides 
details of the methodology.
To attribute an equal lifetime loss produced by a 
death at the same age across the countries,42 43 we 
calculated the YLL from the World Health Organization 
standard life table using the methodology developed 
by the Global Burden of Disease, Injuries and Risk 
Factor study.43 44 The equation in figure 2 was used to 
estimate the YLL.
Calculation of changes in life expectancy at birth 
and YLL in 2015 and 2020
Within each country, sex, and age groups, the reduction 
in life expectancy was calculated as the difference 
between the observed and expected life expectancy 
in 2020. The expected life expectancy for 2020 was 
based on Lee-Carter forecasting using observed 2005-
19 data.39 Similarly, the expected YLL was computed 
for 2020, and excess YLL was calculated as the 
difference between observed and expected YLL within 
each country, sex, and age group. The sum of the 
excess YLL across the age groups, separately by sex, 
was used to estimate country specific total excess YLL 
and excess YLL (per 100 000 population) in 2020. As 
recommended, the excess YLL estimates were rounded 
to three significant digits to avoid spurious accuracy.
We estimated statistical uncertainty using a 
bootstrap method. Following a standard demographic 
approach, we did not calculate confidence intervals for 
life expectancy and YLL at the national level. Thus, we 
considered the mortality forecast as the only source of 
statistical uncertainty. The confidence intervals were 
based on the sample of 5000 iterations generated: 
firstly, we derived a distribution of age specific 
forecasted mortality rates and then we generated a 
random set of age specific death rates and calculated 
our variables of interest (life expectancy, YLL, and 
changes in life expectancy and YLL in 2020). The 
2.5th quantile and the 97.5th quantile of the bootstrap 
distribution for each statistic were used as the 95% 
confidence intervals. The procedure was applied 
independently to each country and sex strata.
Our reference period for predicting mortality in 
2020 is longer than the period of 2015-19 used in 
several earlier studies. The period 2015-19 includes 
substantial increases in mortality during the winters 
of 2015, 2017, and 2018 that contributed to an 
attenuation of the mortality improvements in many 
developed countries in these years.45-47 Consequently, 
the choice of 2015-19 as a reference period might 
result in artificially increased baseline mortality levels 
and underestimation of losses in life expectancy and 
excess YLLs in 2020.
To put our findings into context, we also calculated 
the change in life expectancy and the YLL associated 
with the seasonal influenza epidemic in 2015 following 
the same methodology using data between 2000 and 
2014 as the reference period. We chose 2015 as a 
comparator to 2020 because in 2015 the 37 countries 





STMF (x, x + b) denotes number of deaths in age interval [x, x + b) in the Short-term Mortality
Fluctuations (STMF); D
y 
(x, x + a) is forecasted number of deaths in age interval [x, x + a) in year y,
and D
y 
(x, x + b) is forecasted number of deaths in age interval [x, x + b) in year y,
estimated using information from the Human Mortality Database
(x, x + a) = D
y           
(x, x + b)
D
y
(x, x + a)
D
y
(x, x + b)
STMF STMF
Fig 1 | Equation for splitting aggregated age groups using distribution of forecasted death counts in the Human 
Mortality Database
 on 4 N
ovem













J: first published as 10.1136/bm







4 doi: 10.1136/bmj-2021-066768 | BMJ 2021;375:e066768 | the bmj
improvement in mortality among all years between 
2005 and 2019, coinciding with a noticeable increase 
in mortality during winter.45 48 49
Decomposition of life expectancy losses in the US, 
Lithuania, Poland, and Spain
Earlier research25 33 including our preliminary analysis 
showed the highest life expectancy losses in the US 
compared with other OECD (Organisation for Economic 
Co-operation and Development) countries in 2020. Our 
previous study on excess mortality, however, reported 
the highest excess crude death rates in Lithuania, 
Poland, Spain, Hungary, Italy, Belgium, Slovenia, 
England and Wales, and Czech Republic, followed by 
the US.22 To explain these important discrepancies, 
we conducted an exploratory decomposition analysis 
of the life expectancy losses of 2020 in the US, and 
three countries with highest excess crude death rates 
in 2020 (Lithuania, Poland, and Spain) using the 
Andreev-Arriaga-Pressat method.50-53
Statistical analyses were done using R (version 4.1.0) 
in RStudio. The Lee-Carter forecast was performed 
using the R package demography.54
Patient and public involvement
Patients and the public were not involved in this study 
because of the ongoing covid-19 pandemic.
Results
Changes in life expectancy in 2020
In all the countries between 2005 and 2019, an 
increasing trend was observed in life expectancy at 
birth, both in men and women (supplementary figure 
S3). However, most countries showed a reduction 
in life expectancy in 2020, with the largest overall 
reduction in life expectancy at birth (in years) in Russia 
(−2.32, 95% confidence interval −2.55 to −2.11), the 
US (1.98, −2.16 to 1.82), Bulgaria (−1.75, −2.09 to 
−1.41), Lithuania (−1.61, −1.92 to −1.29), and Poland 
(−1.36, −1.55 to −1.17). Reductions in life expectancy 
in Italy, Spain, and England and Wales were −1.35 
(−1.72 to −0.99), −1.27 (−1.57 to −0.99), and −1.02 
(−1.27 to −0.78), respectively. In contrast, a gain in life 
expectancy was observed in New Zealand (0.66, 0.41 
to 0.89) and Taiwan (0.35, 0.14 to 0.54); no evidence 
was found of a change in life expectancy in South 
Korea (0.11, −0.09 to 0.30), Norway (0.07, −0.03 to 
0.17), or Denmark (−0.09, −0.24 to 0.06) (fig 3).
In all countries but Luxembourg, men had a higher 
reduction in life expectancy at birth than women. The 
reduction in life expectancy in men was highest in Russia 
(−2.33, −2.50 to −2.17), the US (−2.27, −2.39 to −2.15), 
Bulgaria (−1.96, −2.11 to −1.81), Lithuania (−1.83, 
−2.07 to −1.59), and Chile (−1.64, −1.97 to −1.32). In 
women, the reduction in life expectancy was highest in 
Russia (−2.14, −2.25 to −2.03), the US (−1.61, −1.70 
to −1.51), Bulgaria (−1.37, −1.74 to −1.01), Lithuania 
(−1.21, −1.36 to −1.05), and Spain (−1.13, −1.37 to 
−0.90) (fig 3 and supplementary table S2).
Changes in years of life lost in 2020
Years of life lost declined in most countries in both 
men and women between 2005 and 2019, except 
Canada, Greece, Scotland, Taiwan, and the US (fig 4). 
The observed YLL in 2020 was higher than expected in 
all countries except Taiwan and New Zealand, where 
there was a reduction in YLL, and Iceland, South 
Korea, Denmark, and Norway, where there was no 
evidence of a change in YLL in 2020. In the remaining 
31 countries, more than 222 million (130 million in 
men and 92.6 million in women) years of life were 
lost in 2020, which is 28.1 million (95% confidence 
interval 26.8m to 29.5m) YLL higher than expected. 
The excess YLL in men and women were 17.3 million 
(16.8m to 17.8m) and 10.8 million (10.4m to 11.3m), 
respectively.
In men and women combined, excess YLL (per 
100 000) were highest in Russia (5810, 95% 
confidence interval 5280 to 6340), Bulgaria (5440, 
4460 to 6420), Lithuania (3940, 3200 to 4680), the 
US (3380, 3160 to 3610), and Poland (2800, 2430 
to 3170), with a higher rate in men than women. The 
highest excess YLL per 100 000 in men were observed 
in Bulgaria (7260, 6820 to 7710), Russia (7020, 
6550 to 7480), Lithuania (5430, 4750 to 6070), the 
US (4350, 4170 to 4530), and Poland (3830, 3540 to 
4120); excess YLL in women were highest in Russia 
(4760, 4530 to 4990), Bulgaria (3730, 2740 to 4730), 
Lithuania (2640, 2310 to 2980), the US (2430, 2320 
to 2550), and Hungary (1920, 1590 to 2240) (fig 5 and 
supplementary table S3).
Supplementary figure S4 shows the trend of YLL 
during 2005-20 by age and sex. Figure 6 shows the 
excess YLL in 2020 by age and sex. In general, excess 
YLL increased with age, both in men and women. 
However, Finland, Iceland, New Zealand, South 
Korea, and Taiwan had lower than expected YLL in 
the elderly population (≥80 years). These countries 
had a small increase, or a decrease, in YLL in other age 
groups as well (fig 6). Excess YLL rate was generally 
lower in people younger than 65 years, except in 
Russia (3290, 2780 to 3810), Bulgaria (2650, 2220 
to 3070), Lithuania (2580, 1790 to 3410), and the 
US (2390, 2280 to 2510), with excess YLL rate >2000 
per 100 000. The ratio of YLL rate between people 
aged <65 and ≥65 years was 0.2 or higher in Estonia, 










 is number of deaths in country c, sex s, age a, and calendar year t, and SLE
a
is the World Health Organization global health estimates standard life expectancy at age a43
Fig 2 | Equation used to estimate years of life lost (YLL)
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Age components of life expectancy losses in US and 
comparator countries, 2020
Figure 7 shows age components of the life expectancy 
losses in the US, Lithuania, Poland, and Spain in 
men and women produced by differences between 
the observed and expected age specific death rates by 
age intervals 0-14, 15-54, 55-64, 65-74, and ≥75. In 
the US and Lithuania it appears that mortality excess 
in people younger than 65 years, particularly among 
men, was responsible for a high proportion of the 
total losses in life expectancy: the respective values 
for men and women were 62% and 42% in the US and 
58% and 44% in Lithuania. Corresponding values in 
Poland were 27% and 8% and in Spain were 26% and 
15%. These two countries, especially Spain, showed 
an expected pattern, with the dominating role of older 
ages as a driver of losses in life expectancy.
Changes in life expectancy and years of life lost: 
covid-19 (2020) v influenza epidemic (2015)
Most countries experienced a reduction in life 
expectancy in 2015, but the reduction in 2020 was 
substantially greater than that in 2015. Most countries 





























































































































































































































































































































































































































































































Fig 3 | Changes in life expectancy at birth associated with covid-19 pandemic in 2020. Change is calculated as the difference between observed and 
expected life expectancy, estimated using the Lee-Carter model39
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in 2015, except Chile, Estonia, Luxembourg, Latvia, 
Finland, New Zealand, Russia, and Taiwan (fig 8 and fig 
9). The rate of excess YLL was, however, much higher in 
most countries during the covid-19 pandemic in 2020 
compared with the seasonal influenza epidemic in 
2015. Overall, the excess YLL in the 37 countries was 
5.5 times higher during the covid-19 pandemic (2510 
per 100 000, 95% confidence interval 2390 to 2630 
per 100 000) in 2020 than the excess YLL associated 
with the seasonal influenza epidemic in 2015 (458, 
325 to 592), with an absolute difference of 2050 years 
of life lost per 100 000.
Discussion
In this global comparative study of 37 countries, a 
reduction in life expectancy was found in men and 
women in all countries except New Zealand, Taiwan, 
and Norway, where there was a gain in life expectancy 
WomenMen





























































































































































Fig 4 | Years of life lost (YLL) per 100 000 during 2005-20
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in 2020. We found no evidence of a change in life 
expectancy in 2020 in Denmark, Iceland, and South 
Korea. The highest reduction in life expectancy in men 
was observed in Russia, the US, Bulgaria, Lithuania, 
and Chile; the highest reduction in women was 
observed in Russia, the US, Bulgaria, Lithuania, and 
Spain. Years of life lost were higher than expected in 
all countries except Taiwan, New Zealand, Iceland, 
Denmark, South Korea, and Norway. In the remaining 
31 countries, about 28 million excess years of life 
were lost in 2020 (17 million in men and 11 million 
in women). The highest excess YLL in both men and 
women were observed in Russia, Bulgaria, Lithuania, 
the US, and Poland. The excess YLL rate was relatively 
low in people younger than 65 years, except in Russia, 
the US, Lithuania, and Bulgaria. The excess YLL rates 
associated with the covid-19 pandemic in 2020 were 
more than five times higher than those associated with 
the seasonal influenza epidemic in 2015.
Comparison with previous literature
Country specific estimates of life expectancy, largely 
based on partial data in 2020, have been reported 
























































































































































































































































































































































































































































































Fig 5 | Excess years of life lost (YLL) in 2020 (per 100 000). Change is calculated as the difference between observed and expected life expectancy 
estimated using Lee-Carter model39
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In the US, the trajectory of life expectancy at birth 
during 2010-20 reported in our study is similar to 
that reported by the Centers for Disease Control and 
Prevention (CDC).27 Drawing on data from the first 
half of 2020, this study reported a life expectancy 
of 77.8 years in the US,27 whereas the estimated 
life expectancy at birth in our study was 77.4 years. 
Similarly, our estimates of life expectancy at birth were 
74.6 years in men and 80.3 years in women, which 
was slightly lower than those reported in the CDC study 
(75.1 and 80.5 years, respectively).27 These differences 
could be due to a varying timeline used to estimate life 
expectancy—the CDC study used data up to June 2020, 
whereas we used data for the full year. Moreover, our 
earlier study showed that the excess death rates in the 
younger age groups (15-64 years) increased during 
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Fig 6 | Excess years of life lost (YLL) (per 100 000) by age and sex in 2020
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In Aburto and colleagues’ study of England and 
Wales, using data up to the 47th week (ending 20 
November) of 2020, the estimated life expectancy was 
82.6 years in women and 78.7 years in men.29 These 
findings are almost identical to the estimates from our 
study (82.7 and 78.7 years, respectively).
Using data up to 5 July 2020, a previous study 
reported an estimated life expectancy of 79.5 and 
85.0 years in men and women, respectively, in Spain 
in 2020.26 These estimates are almost identical to 
those from our study (79.6 and 85.0 years in men and 
women, respectively).
Multi-country life expectancy estimates and analyses 
of life expectancy losses across countries have recently 
been published.55 In particular, the Eurostat has 
published preliminary estimates of life expectancy 
at birth for member countries of the European Union. 
Comparison between these estimates and our estimates 
was possible for 26 countries. For 21 countries, the 
differences were 0.1 years or lower (in both men and 
women), which is attributable to different methods 
for building abridged life tables and some remaining 
incompleteness of mortality data. The largest deviations 
(0.3 years) were seen in the small populations of 
Iceland, Latvia, and Luxembourg as well as Finland. 
However, the updated life expectancy estimates by 
Statistics Finland are similar to our estimates.56
A previous analysis reported the change in life 
expectancy across 29 developed countries.33 Our 
analysis includes eight additional countries. We were 
able to include data from Canada, Israel, South Korea, 
New Zealand, Luxembourg, and Latvia because we 
applied a more efficient procedure for estimation of the 
detailed mortality age distributions that fully exploited 
all available data from the Human Mortality Database. 
Taiwan was included because updates to Short-term 
Mortality Fluctuations allowed us to fill former data 
gaps. Russia was included because Russian data 
for 2020 has recently been included in Short-term 
Mortality Fluctuations. Data for these additional eight 
countries allowed us to observe most of the range of 
losses in life expectancy in developed countries as well 
as to highlight the favourable situation in New Zealand, 
Taiwan, and South Korea. For the subset of 29 countries 
present in both the studies, the life expectancy losses 
are in a good agreement with a Spearman’s correlation 
coefficient of 0.94 between the two rankings.
Most of the studies that reported on YLL used deaths 
with covid-19 to estimate potential YLL.23 30-32 One 
earlier study examined the change in YLL due to excess 
deaths from all causes in 19 developed countries.23 All 
these studies, however, used country specific remaining 
life expectancies, and in this sense the estimated YLL 
are not comparable across the countries. Since deaths 
with covid-19 might result in an underestimation or, 
in some cases, overestimation of the overall impact of 
the pandemic on deaths and YLL, our estimates are 
not directly comparable to these estimates. One study 
estimated 20.5 million YLL in 81 countries based on 
projected deaths with covid-19,23 whereas our study 
estimated 28.1 million YLL in only 31 countries. These 
findings suggest a substantial underestimation of the 
overall impact on premature mortality if the estimates 
are based solely on deaths with covid-19 or when the 
estimation of YLL uses country specific life tables, or 
both. Moreover, covid-19 mortality data are often not 
disaggregated by age at the levels (eg, five year age 
categories) required for an accurate estimation of life 
expectancy and premature deaths.
With a much lower reported number of deaths with 
covid-19 (n=1613) in Lithuania, the estimated excess 
YLL were higher than in most of the countries (except 
Bulgaria and Hungary), as were the estimated excess 
deaths in a previous study.22 Our study found that 
the additional years of life lost associated with the 
covid-19 pandemic in 2020 were higher than those 
associated with the seasonal influenza epidemic in 
2015, which is consistent with a previous report.32 
Our finding of comparable or lower than expected YLL 
in 2020 in Taiwan, New Zealand, Iceland, and South 
Korea could be attributed to the successful pandemic 
elimination policies of these countries, including 
evidence based population health interventions.57-62 
Taiwan and New Zealand also had lower than expected 
YLL during the seasonal influenza epidemic in 2015. 
Exploring the precise reasons for this is beyond the 
scope of this study but could potentially be related 
to policy interventions, including seasonal influenza 
vaccine coverage and systemic resilience of the public 
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Fig 7 | Age group components of difference between observed and expected life 
expectancy (LE) in 2020 among men and women in the United States and three 
comparator countries with the highest excess crude death rates in 2020. *Highest 
excess death rates according to Islam et al.22 The life table decomposition analysis was 
conducted using the Andreev-Arriaga-Pressat method50 51-53
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interventions aimed at reducing the transmission of 
SARS-CoV-21 might have had other indirect effects 
(eg, a reduction in deaths from other causes, such 
as influenza and other respiratory infections, air 
pollution, road traffic incidents) contributing to an 
overall reduction in YLL in 2020.
Strengths and limitations of this study
In addition to using the two major public health 
measures reflecting prematurity of death and 
accounting for trends, a key strength of our study was 
use of validated and standardised mortality data from 
authoritative national agencies to ensure comparability 
across countries and time. Rather than relying on 
deaths with covid-19, we used all cause mortality 
data in our analysis, which are less sensitive to coding 
error and misclassification in attributing the cause 
of deaths. We also estimated the expected YLL based 
on 15 years of historical data and applied a validated 
analytical approach that enables a more effective use 
of available data from the Human Mortality Database, 
which in turn allowed us to include more countries 
in the analysis. Rather than using an arbitrary age 
threshold, we used WHO standard life expectancy to 
enable international comparison of YLL following 





















































































































































































































































































































































































































































































































Fig 8 | Changes in life expectancy during covid-19 pandemic in 2020 compared with seasonal influenza epidemic in 2015
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Disease, Injuries and Risk Factor study.43 44 Our study 
does, however, have some limitations. Firstly, our 
study was restricted to countries with reliable data 
for the whole study period of 2000-20. Therefore, we 
did not include most countries from Asia, Africa, and 
Latin America. Our assumption of a no migration for 
population projection, when applicable, might not 
be generalisable to analyses at subnational levels. 
We also could not examine the variation in excess 
YLL by other critically important factors, such as 
socioeconomic status and race or ethnicity.64-71 
Previous studies also reported regional variability in 
reduction in life expectancy, such as in Spain,26 but 
we did not have detailed regional data to examine this 
important heterogeneity. Our study only reports the 
extent of premature lives lost in 2020. As of October 
2021, however, the covid-19 pandemic is not yet over, 
and therefore future studies should estimate the long 
term burden of the pandemic.
Policy implications and future directions
Our findings extend the existing literature on the 
direct and indirect effects of the covid-19 pandemic 
and associated policy measures.22 Our results strongly 
justify a more nuanced estimation of the lives lost 





























































































































































































































































































































































































































































































































Fig 9 | Changes in years of life lost (YLL) (per 100 000) during covid-19 pandemic in 2020 compared with seasonal influenza epidemic in 2015
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burden of excess deaths per 100 000 in Spain and 
the US (161 and 160, respectively),22 excess YLL (per 
100 000) was substantially higher in the US (3400) than 
in Spain (1900), indicating higher numbers of deaths 
at younger ages in the US compared with Spain.22 
Indeed, the ratio of YLL rate in people aged <65 and 
≥65 years at death was 0.29 in the US, whereas it was 
only 0.07 in Spain. Despite a lower excess death rate 
than Lithuania, Poland, and Spain,22 the reduction in 
life expectancy in the US was higher than in these three 
countries. A full examination of this phenomenon is 
beyond the scope of the current study. Nevertheless, 
the decomposition analysis of the life expectancy 
losses in these four countries reveals particularly large 
contributions to the reduction of life expectancy from 
increases in mortality at ages younger than 65 years in 
the US. However, our analyses were not able to identify 
whether these excess deaths were directly caused by 
SARS-CoV-2 or were related to other causes of deaths. 
The highest reduction in life expectancy, and highest 
increase in YLL, largely occurred in countries where the 
baseline life expectancy was relatively low. Therefore, 
baseline health status could have contributed to these 
results. Widespread ethnic inequality in the US, as 
reported previously, might have contributed to high 
YLL in the US.25 Future studies should conduct an in-
depth examination to disentangle these factors.
Our findings of a comparable or lower than expected 
YLL in Taiwan, New Zealand, Denmark, Iceland, 
Norway, and South Korea underscore the importance of 
successful viral suppression and elimination policies, 
including targeted and population based public 
health policy interventions.57-62 A comprehensive 
pandemic preparedness aimed at more resilient health 
systems could be key to tackling the impact of future 
pandemics.3 63 Quantifying the effects of specific policy 
interventions on the reduction of premature deaths 
will help inform future policy intervention. As many of 
the effects of the pandemic might take a longer time 
frame to have a measurable effect on human lives, 
continuous and timely monitoring of excess YLL would 
help identify the sources of excess mortality and excess 
YLL in population subgroups.72
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